Free Trial
→ I’m sounding the alarm (From Porter & Company) (Ad)tc pixel Free MDGL Stock Alerts

Madrigal Pharmaceuticals (MDGL) Financials

Madrigal Pharmaceuticals logo
$522.23 -1.46 (-0.28%)
Closing price 04:00 PM Eastern
Extended Trading
$508.50 -13.73 (-2.63%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Madrigal Pharmaceuticals

Annual Income Statements for Madrigal Pharmaceuticals

This table shows Madrigal Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -69 -26 -31 -33 -84 -202 -242 -295 -374 -466 -288
Consolidated Net Income / (Loss)		 -69 -26 -31 -33 -84 -202 -242 -295 -374 -466 -288
Net Income / (Loss) Continuing Operations		 -69 -26 -31 -33 -84 -202 -242 -295 -374 -466 -288
Total Pre-Tax Income 		-69 -26 -31 -33 -84 -202 -242 -295 -374 -466 -288
Total Operating Income		 -68 -25 -32 -41 -95 -207 -242 -294 -380 -498 -300
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 180 958
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 180 958
Operating Revenue		 - - - 0.00 0.00 0.00 - 0.00 0.00 180 958
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 68 25 32 41 95 207 242 294 380 678 1,259
Selling, General & Admin Expense		 13 9.29 7.67 15 23 22 37 48 108 441 870
Research & Development Expense		 54 16 24 25 72 185 205 245 272 237 389
Total Other Income / (Expense), net		 -1.06 -1.17 0.91 7.87 11 4.43 0.64 -1.78 6.87 32 12
Interest Expense		 - 1.21 - - - 0.00 0.00 3.96 13 15 25
Interest & Investment Income		 -1.06 0.05 0.56 7.67 11 4.33 0.36 2.19 20 47 37
Other Income / (Expense), net		 - 0.00 0.35 0.20 0.00 0.10 0.27 - 0.00 0.00 -0.46
Basic Earnings per Share		 ($0.53) ($5.07) ($2.54) ($2.22) ($5.45) ($13.09) ($14.63) ($17.23) ($19.99) ($21.90) ($12.85)
Weighted Average Basic Shares Outstanding		 137.81M 5.20M 12.24M 14.80M 15.39M 15.45M 16.54M 17.14M 18.69M 21.27M 22.43M
Diluted Earnings per Share		 ($0.53) ($5.07) ($2.54) ($2.22) ($5.45) ($13.09) ($14.63) ($17.23) ($19.99) ($21.90) ($12.85)
Weighted Average Diluted Shares Outstanding		 137.81M 5.20M 12.24M 14.80M 15.39M 15.45M 16.54M 17.14M 18.69M 21.27M 22.43M
Weighted Average Basic & Diluted Shares Outstanding		 128.59M 5.20M 12.24M 14.80M 15.39M 15.45M 16.54M 18.14M 19.90M 22.08M 22.94M

Quarterly Income Statements for Madrigal Pharmaceuticals

This table shows Madrigal Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -99 -112 -148 -152 -107 -59 -73 -42 -114 -59 -94
Consolidated Net Income / (Loss)		 -99 -112 -148 -152 -107 -59 -73 -42 -114 -59 -94
Net Income / (Loss) Continuing Operations		 -99 -112 -148 -152 -107 -59 -73 -42 -114 -59 -94
Total Pre-Tax Income 		-99 -112 -148 -152 -107 -59 -73 -42 -114 -59 -94
Total Operating Income		 -99 -117 -152 -163 -116 -67 -79 -47 -114 -60 -93
Total Gross Profit		 0.00 - 0.00 15 62 97 137 213 287 321 311
Total Revenue		 0.00 - 0.00 15 62 103 137 213 287 321 311
Operating Revenue		 0.00 - 0.00 15 62 - 137 213 287 321 311
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 6.23 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 99 117 152 177 178 164 217 260 401 381 404
Selling, General & Admin Expense		 28 47 81 106 110 138 172 206 227 264 295
Research & Development Expense		 71 71 71 71 69 26 44 54 174 116 109
Total Other Income / (Expense), net		 -0.21 4.98 4.50 11 9.34 7.58 6.07 4.92 -0.22 1.03 -1.67
Interest Expense		 3.50 3.97 3.84 3.66 3.68 3.50 3.30 3.26 10 8.30 7.82
Interest & Investment Income		 3.30 8.95 8.33 14 13 11 9.37 8.23 10 9.46 8.24
Other Income / (Expense), net		 - - - 0.00 0.00 - 0.00 -0.04 -0.29 - -2.09
Basic Earnings per Share		 ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50) ($2.61) ($1.90) ($5.08) ($2.55) ($3.25)
Weighted Average Basic Shares Outstanding		 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M 28.09M 22.21M 22.48M 22.43M 29.03M
Diluted Earnings per Share		 ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50) ($2.61) ($1.90) ($5.08) ($2.55) ($3.25)
Weighted Average Diluted Shares Outstanding		 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M 28.09M 22.21M 22.48M 22.43M 29.03M
Weighted Average Basic & Diluted Shares Outstanding		 19.74M 19.90M 21.31M 21.71M 21.81M 22.08M 22.20M 22.29M 22.71M 22.94M 23.06M

Annual Cash Flow Statements for Madrigal Pharmaceuticals

This table details how cash moves in and out of Madrigal Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.16 19 129 -91 -11 7.31 -18 295 -232 5.10 99
Net Cash From Operating Activities		 -3.14 -18 -22 -26 -42 -158 -184 -225 -324 -456 -190
Net Cash From Continuing Operating Activities		 -3.14 -18 -22 -26 -42 -158 -184 -225 -324 -456 -190
Net Income / (Loss) Continuing Operations		 -6.84 -26 -31 -33 -84 -202 -242 -295 -374 -466 -288
Consolidated Net Income / (Loss)		 -6.84 -26 -31 -33 -84 -202 -242 -295 -374 -466 -288
Depreciation Expense		 - 0.00 0.08 0.10 0.11 0.47 0.41 0.47 0.53 1.10 1.51
Amortization Expense		 - - - - - 0.00 0.00 0.80 2.41 1.69 4.81
Non-Cash Adjustments To Reconcile Net Income		 3.61 9.89 3.25 9.82 26 23 28 32 44 56 107
Changes in Operating Assets and Liabilities, net		 0.09 -1.11 5.51 -2.61 16 22 30 38 2.17 -48 -14
Net Cash From Investing Activities		 0.00 22 -22 -380 31 160 -5.06 207 -503 -274 32
Net Cash From Continuing Investing Activities		 0.00 22 -22 -380 31 160 -5.06 207 -503 -274 32
Purchase of Property, Plant & Equipment		 - -0.00 -0.13 -0.02 -0.17 -0.33 -0.21 -0.22 -1.48 -1.46 -0.47
Acquisitions		 - - - - - - - 0.00 0.00 -5.00 -3.00
Purchase of Investments		 - -11 -70 -614 -619 -329 -394 -143 -834 -1,131 -1,048
Sale and/or Maturity of Investments		 - 26 48 234 650 489 389 350 333 863 1,083
Net Cash From Financing Activities		 3.30 14 174 314 0.24 5.09 171 313 595 735 256
Net Cash From Continuing Financing Activities		 3.30 14 174 314 0.24 5.09 171 313 595 735 256
Repayment of Debt		 - - - - - 0.00 0.00 -0.89 -0.36 0.00 -132
Issuance of Debt		 2.80 8.50 - - - 0.00 0.00 50 65 0.00 350
Issuance of Common Equity		 0.00 0.00 - 312 0.00 4.42 171 264 530 735 38
Effect of Exchange Rate Changes		 - - - - - - - - 0.00 0.00 0.01

Quarterly Cash Flow Statements for Madrigal Pharmaceuticals

This table details how cash moves in and out of Madrigal Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -15 38 523 -123 -262 -133 84 2.55 110 -97 28
Net Cash From Operating Activities		 -85 -80 -149 -135 -67 -104 -89 -47 80 -133 -167
Net Cash From Continuing Operating Activities		 -85 -80 -149 -135 -67 -105 -89 -47 80 -133 -167
Net Income / (Loss) Continuing Operations		 -99 -112 -148 -152 -107 -59 -73 -42 -114 -59 -94
Consolidated Net Income / (Loss)		 -99 -112 -148 -152 -107 -59 -73 -42 -114 -59 -94
Depreciation Expense		 0.14 0.14 0.17 0.27 0.30 0.36 0.38 0.38 0.36 0.39 0.39
Amortization Expense		 0.67 0.75 0.66 0.47 0.48 0.08 0.49 0.43 1.88 2.02 0.86
Non-Cash Adjustments To Reconcile Net Income		 13 13 19 15 18 4.34 24 27 29 28 34
Changes in Operating Assets and Liabilities, net		 -0.08 19 -21 1.76 21 -50 -40 -32 163 -105 -108
Net Cash From Investing Activities		 50 -362 98 -122 -202 -48 164 48 -207 28 192
Net Cash From Continuing Investing Activities		 50 -362 98 -122 -202 -48 164 48 -207 28 192
Purchase of Property, Plant & Equipment		 -0.34 -1.04 -0.36 -0.13 -0.78 -0.20 0.00 - -0.86 0.39 -3.85
Purchase of Investments		 -69 -475 -84 -281 -416 -350 -131 -226 -478 -213 -158
Sale and/or Maturity of Investments		 119 114 183 164 214 302 295 273 275 240 354
Net Cash From Financing Activities		 20 480 574 134 7.46 20 8.64 1.74 237 8.96 2.33
Net Cash From Continuing Financing Activities		 20 480 574 134 7.46 20 8.64 1.74 237 8.96 2.33
Other Financing Activities, net		 - - - - - - 8.64 - - - 2.33
Effect of Exchange Rate Changes		 - - - - - - 0.00 - - - 1.32

Annual Balance Sheets for Madrigal Pharmaceuticals

This table presents Madrigal Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.36 41 192 485 442 287 273 363 641 1,042 1,260
Total Current Assets		 0.36 41 192 485 440 285 272 361 637 1,033 1,246
Cash & Equivalents		 0.31 19 149 57 47 54 36 332 100 100 199
Restricted Cash		 - - - - - - - - 0.00 5.00 5.09
Short-Term Investments		 - 21 43 426 392 230 234 27 534 826 785
Accounts Receivable		 0.01 - - - - - - - 0.00 54 134
Inventories, net		 - - - - - - - - 0.00 34 75
Prepaid Expenses		 0.05 0.71 0.49 1.48 1.15 1.01 1.34 2.60 3.15 14 48
Plant, Property, & Equipment, net		 0.00 0.00 0.30 0.23 1.18 1.05 0.85 0.60 1.55 2.19 1.50
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.68 0.79 0.80 0.60 1.71 7.13 12
Intangible Assets		 - - - - - - - - 0.00 4.73 7.38
Other Noncurrent Operating Assets		 - - - - 0.68 0.79 0.80 0.60 1.71 2.40 4.94
Total Liabilities & Shareholders' Equity		 0.36 41 192 485 442 287 273 363 641 1,042 1,260
Total Liabilities		 49 4.80 10 8.44 25 47 77 165 235 288 657
Total Current Liabilities		 49 4.80 10 8.44 25 47 77 116 119 169 310
Accounts Payable		 0.10 0.76 1.93 2.49 1.18 1.02 21 24 28 44 49
Accrued Expenses		 0.07 4.04 8.13 5.96 24 45 55 91 90 125 260
Other Current Liabilities		 - - - - 0.32 0.32 0.41 0.60 0.53 0.98 1.02
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.36 0.47 0.39 49 117 119 347
Long-Term Debt		 - - - - - - 0.00 49 115 118 340
Other Noncurrent Operating Liabilities		 - - - - 0.36 0.47 0.39 0.00 1.19 1.02 6.73
Total Equity & Noncontrolling Interests		 -49 36 182 477 417 240 196 197 405 754 603
Total Preferred & Common Equity		 -49 36 182 477 417 240 196 197 405 754 603
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -49 36 182 477 417 240 196 197 405 754 603
Common Stock		 0.01 112 289 617 640 665 863 1,160 1,741 2,556 2,692
Retained Earnings		 -49 -75 -106 -139 -223 -425 -667 -963 -1,336 -1,802 -2,090
Accumulated Other Comprehensive Income / (Loss)		 - 0.03 -0.03 -0.32 0.22 0.05 -0.08 -0.03 0.47 0.47 0.87

Quarterly Balance Sheets for Madrigal Pharmaceuticals

This table presents Madrigal Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 159 332 302 238 1,082 1,100 1,073 997 1,015 1,362 1,227
Total Current Assets		 157 331 302 235 1,074 1,092 1,064 988 1,003 1,347 1,182
Cash & Equivalents		 59 113 77 62 623 495 233 184 186 296 227
Restricted Cash		 - - - - - 5.00 5.00 5.00 5.00 5.00 5.16
Short-Term Investments		 94 216 221 170 437 563 766 659 611 814 586
Accounts Receivable		 - - - - - 6.90 30 61 79 113 187
Inventories, net		 - - - - 0.85 7.07 8.72 55 63 69 112
Prepaid Expenses		 3.92 1.81 3.18 3.12 14 15 21 23 59 49 65
Plant, Property, & Equipment, net		 0.70 0.51 0.46 0.66 1.74 1.70 2.27 1.90 1.62 2.91 8.04
Total Noncurrent Assets		 0.83 0.65 0.41 1.84 6.59 6.37 7.33 6.75 10 13 37
Intangible Assets		 - - - - 5.00 4.91 4.82 4.64 4.55 7.48 7.28
Other Noncurrent Operating Assets		 0.83 0.65 0.41 1.84 1.59 1.46 2.51 2.11 5.86 5.39 30
Total Liabilities & Shareholders' Equity		 159 332 302 238 1,082 1,100 1,073 997 1,015 1,362 1,227
Total Liabilities		 148 182 199 216 232 243 296 286 319 737 684
Total Current Liabilities		 99 98 100 100 114 125 178 167 197 391 338
Accounts Payable		 19 12 18 17 22 8.99 46 42 38 45 61
Accrued Expenses		 80 86 82 83 92 116 131 124 157 345 276
Other Current Liabilities		 0.76 0.65 0.41 0.51 0.54 0.56 0.88 1.02 1.05 1.08 1.70
Total Noncurrent Liabilities		 49 84 99 116 117 118 118 119 123 345 346
Long-Term Debt		 49 84 99 115 116 117 117 118 118 340 340
Other Noncurrent Operating Liabilities		 0.07 - - 1.32 1.05 0.90 1.18 0.75 4.52 5.57 5.28
Total Equity & Noncontrolling Interests		 11 150 104 22 851 857 777 711 696 626 543
Total Preferred & Common Equity		 11 150 104 22 851 857 777 711 696 626 543
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 11 150 104 22 851 857 777 711 696 626 543
Common Stock		 888 1,190 1,229 1,246 2,335 2,493 2,519 2,586 2,613 2,657 2,727
Retained Earnings		 -877 -1,040 -1,125 -1,224 -1,484 -1,636 -1,743 -1,875 -1,918 -2,032 -2,185
Accumulated Other Comprehensive Income / (Loss)		 -0.24 -0.09 -0.09 -0.04 -0.17 -0.37 1.27 0.39 1.11 1.07 1.08

Annual Metrics And Ratios for Madrigal Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Madrigal Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 432.05%
EBITDA Growth		 18.81% 0.00% -25.42% -27.66% -134.88% -117.27% -17.32% -20.89% -29.16% -31.13% 40.57%
EBIT Growth		 19.46% 0.00% -25.73% -27.66% -134.60% -117.51% -17.25% -21.21% -29.61% -30.85% 39.63%
NOPAT Growth		 19.46% 0.00% -27.11% -26.89% -133.45% -117.61% -17.33% -21.07% -29.61% -30.85% 39.72%
Net Income Growth		 20.30% 0.00% -18.06% -5.32% -155.85% -140.92% -19.58% -22.12% -26.50% -24.69% 38.12%
EPS Growth		 39.08% 0.00% 49.90% 12.60% -145.50% -140.18% -11.76% -17.77% -16.02% -9.55% 41.32%
Operating Cash Flow Growth		 96.02% -460.44% -26.74% -14.29% -63.19% -278.53% -16.73% -22.26% -44.19% -40.51% 58.39%
Free Cash Flow Firm Growth		 -10.57% 0.00% 0.00% -79.62% -63.60% -142.38% -13.58% -20.02% -58.15% -51.83% 44.53%
Invested Capital Growth		 96.65% 0.00% -126.60% 27.34% -233.83% -96.53% -68.04% -50.99% -1.09% 47.67% 22.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 134.51% 29.40%
EBITDA Q/Q Growth		 -11.55% 0.00% 0.00% 0.00% -19.53% -16.65% -2.14% -7.49% -9.08% 9.13% 2.79%
EBIT Q/Q Growth		 -11.55% 0.00% 0.00% 0.00% -19.50% -16.66% -2.13% -7.59% -9.14% 9.16% 2.25%
NOPAT Q/Q Growth		 -11.55% 0.00% 0.00% 0.00% -19.50% -16.72% -2.13% -7.59% -9.14% 9.16% 2.40%
Net Income Q/Q Growth		 -9.60% 0.00% 0.00% 0.00% -24.03% -18.37% -2.30% -7.79% -7.57% 10.18% 0.29%
EPS Q/Q Growth		 93.87% 0.00% 0.00% 0.00% -23.58% -18.25% 0.14% -7.35% -3.90% 12.85% -0.39%
Operating Cash Flow Q/Q Growth		 85.22% -31.17% -3.07% -1.27% -16.90% -37.13% 3.61% -4.88% -7.07% -5.70% -18.04%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -35.17% 5.74% -3.65% -9.47% -8.90% -27.33%
Invested Capital Q/Q Growth		 97.01% 0.00% 0.00% 0.00% -69.52% 4.44% -15.52% -19.84% -18.81% 45.79% 69.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 96.54% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -274.85% -30.70%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -276.39% -31.31%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -276.39% -31.36%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -258.64% -30.08%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.57% 104.62% 98.24% 81.05% 88.39% 97.90% 99.85% 100.61% 98.20% 93.58% 95.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -846.61% 422.09% -28.49% -9.95% -18.79% -61.61% -110.92% -150.12% -123.98% -80.35% -42.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -59.17% -26.11%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -55.37% -25.05%
Return on Common Equity (ROCE)		 -846.61% 422.09% -28.49% -9.95% -18.79% -61.61% -110.92% -150.12% -123.98% -80.35% -42.49%
Return on Equity Simple (ROE_SIMPLE)		 140.39% -72.47% -17.09% -6.88% -20.15% -84.28% -123.32% -149.63% -92.18% -61.76% 0.00%
Net Operating Profit after Tax (NOPAT)		 -47 -18 -22 -28 -66 -145 -170 -205 -266 -349 -210
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -193.48% -21.92%
Net Nonoperating Expense Percent (NNEP)		 -120.26% -21.56% -7.51% -1.28% -3.79% -15.92% -26.01% -30.99% -25.91% -17.62% -10.70%
Return On Investment Capital (ROIC_SIMPLE)		 14,873.68% - - - - - - -83.31% -51.14% -39.97% -22.29%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.46% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 241.52% 90.77%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 131.41% 40.54%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 372.93% 131.31%
Earnings before Interest and Taxes (EBIT)		 -68 -25 -32 -40 -95 -207 -242 -294 -380 -498 -301
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -68 -25 -32 -40 -95 -206 -242 -292 -378 -495 -294
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 4.73 6.29 3.64 3.37 7.17 7.39 25.15 11.27 8.92 21.94
Price to Tangible Book Value (P/TBV)		 0.00 4.73 6.29 3.64 3.37 7.17 7.39 25.15 11.27 8.98 22.22
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 37.36 13.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32.84 13.12
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.99 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.28 0.16 0.56
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.28 0.16 0.56
Financial Leverage		 -2.19 -1.11 -1.06 -1.02 -1.03 -1.10 -1.27 -1.47 -1.37 -1.15 -1.08
Leverage Ratio		 6.23 -3.33 1.07 1.03 1.04 1.11 1.28 1.62 1.66 1.45 1.70
Compound Leverage Factor		 6.33 -3.48 1.05 0.83 0.92 1.09 1.28 1.63 1.63 1.36 1.63
Debt to Total Capital		 -15,272.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.98% 22.17% 13.48% 36.06%
Short-Term Debt to Total Capital		 -15,272.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.98% 22.17% 13.48% 36.06%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 15,372.23% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 80.02% 77.83% 86.52% 63.94%
Debt to EBITDA		 -0.72 0.00 0.00 0.00 0.00 0.00 0.00 -0.17 -0.31 -0.24 -1.16
Net Debt to EBITDA		 -0.71 0.00 0.00 0.00 0.00 0.00 0.00 1.06 1.37 1.64 2.20
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.17 -0.31 -0.24 -1.16
Debt to NOPAT		 -1.03 0.00 0.00 0.00 0.00 0.00 0.00 -0.24 -0.43 -0.34 -1.62
Net Debt to NOPAT		 -1.02 0.00 0.00 0.00 0.00 0.00 0.00 1.51 1.95 2.33 3.09
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.24 -0.43 -0.34 -1.62
Altman Z-Score		 -962.87 18.03 68.27 123.79 32.80 18.49 5.77 12.46 7.74 11.20 10.62
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.01 8.58 19.10 57.46 17.52 6.13 3.54 3.12 5.38 6.10 4.01
Quick Ratio		 0.01 8.44 19.05 57.29 17.47 6.10 3.52 3.10 5.35 5.79 3.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -65 0.00 -17 -31 -51 -123 -140 -168 -265 -403 -223
Operating Cash Flow to CapEx		 0.00% 0.00% -17,853.60% -115,940.91% -24,200.00% -47,173.95% -87,998.56% -103,620.74% -21,922.24% -31,160.88% -40,589.51%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -42.29 -20.86 -27.44 -8.90
Operating Cash Flow to Interest Expense		 0.00 -14.52 0.00 0.00 0.00 0.00 0.00 -56.72 -25.51 -31.05 -7.56
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -13.94 0.00 0.00 0.00 0.00 0.00 -56.78 -25.62 -31.15 -7.57
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.83
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.18
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.25 519.60
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 35.86
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,097.59 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,097.59 35.86
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.62 -4.09 -9.27 -6.73 -22 -44 -74 -112 -113 -59 -46
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.09 -18.19
Increase / (Decrease) in Invested Capital		 18 0.00 -5.18 2.53 -16 -22 -30 -38 -1.22 54 13
Enterprise Value (EV)		 97 132 955 1,251 967 1,435 1,178 4,655 4,049 5,916 12,577
Market Capitalization		 49 172 1,147 1,735 1,406 1,719 1,449 4,964 4,568 6,730 13,226
Book Value per Share		 ($0.36) $3.15 $14.59 $30.99 $27.00 $15.52 $11.47 $11.54 $20.53 $34.59 $26.54
Tangible Book Value per Share		 ($0.36) $3.15 $14.59 $30.99 $27.00 $15.52 $11.47 $11.54 $20.53 $34.37 $26.21
Total Capital		 -0.32 36 182 477 417 240 196 247 521 872 943
Total Debt		 49 0.00 0.00 0.00 0.00 0.00 0.00 49 115 118 340
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 49 115 118 340
Net Debt		 48 -41 -192 -484 -439 -284 -270 -309 -519 -814 -649
Capital Expenditures (CapEx)		 0.00 -0.70 0.13 0.02 0.17 0.33 0.21 0.22 1.48 1.46 0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.62 -4.09 -9.57 -6.96 -24 -46 -76 -113 -115 -68 -53
Debt-free Net Working Capital (DFNWC)		 -0.32 36 182 477 415 239 195 245 519 864 935
Net Working Capital (NWC)		 -49 36 182 477 415 239 195 245 519 864 935
Net Nonoperating Expense (NNE)		 21 8.73 8.71 4.33 17 58 72 90 107 117 78
Net Nonoperating Obligations (NNO)		 48 -41 -192 -484 -439 -284 -270 -309 -519 -814 -649
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.08 0.10 0.11 0.47 0.41 1.26 2.94 2.79 6.32
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -37.53% -5.55%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 479.45% 97.61%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 479.45% 97.61%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($18.55) ($5.07) ($2.54) ($2.22) ($5.45) $0.00 $0.00 $0.00 ($19.99) ($21.90) ($12.85)
Adjusted Weighted Average Basic Shares Outstanding		 3.94M 12.17M 14.23M 15.42M 15.43M 0.00 0.00 0.00 18.69M 21.27M 22.43M
Adjusted Diluted Earnings per Share		 ($18.55) ($5.07) ($2.54) ($2.22) ($5.45) $0.00 $0.00 $0.00 ($19.99) ($21.90) ($12.85)
Adjusted Weighted Average Diluted Shares Outstanding		 3.94M 12.17M 14.23M 15.42M 15.43M 0.00 0.00 0.00 18.69M 21.27M 22.43M
Adjusted Basic & Diluted Earnings per Share		 ($18.55) ($5.07) ($2.54) ($2.22) ($5.45) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.67M 5.20M 12.24M 14.80M 15.39M 0.00 0.00 0.00 19.90M 22.08M 22.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -47 -18 -22 -28 -66 -145 -170 -205 -266 -349 -210
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -193.48% -21.92%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -258.64% -30.08%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -20.79 0.00 0.00 0.00 0.00 0.00 -74.06 -29.93 -33.94 -11.98
NOPAT to Interest Expense		 0.00 -14.56 0.00 0.00 0.00 0.00 0.00 -51.84 -20.95 -23.76 -8.37
EBIT Less CapEx to Interest Expense		 0.00 -20.22 0.00 0.00 0.00 0.00 0.00 -74.11 -30.05 -34.04 -12.00
NOPAT Less CapEx to Interest Expense		 0.00 -13.98 0.00 0.00 0.00 0.00 0.00 -51.90 -21.07 -23.85 -8.39
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Madrigal Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Madrigal Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 22,939,969.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 22,939,969.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -4.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,353.76% 362.03% 210.77% 126.84%
EBITDA Growth		 -22.19% -37.02% -94.41% -88.64% -18.22% 42.77% 48.13% 71.30% 3.41% 13.46% -19.29%
EBIT Growth		 -22.54% -37.37% -94.08% -88.01% -18.03% 42.82% 47.83% 70.93% 1.75% 11.03% -19.55%
NOPAT Growth		 -22.54% -37.37% -94.08% -88.01% -18.03% 42.82% 47.83% 70.96% 2.00% 11.03% -16.91%
Net Income Growth		 -21.61% -30.60% -91.87% -77.12% -8.33% 47.04% 50.36% 72.18% -6.76% 1.42% -28.88%
EPS Growth		 -12.42% -15.06% -74.47% -51.39% 7.87% 56.37% 55.01% 73.24% -3.25% -2.00% -24.52%
Operating Cash Flow Growth		 -43.76% -36.60% -77.43% -79.19% 21.12% -30.72% 40.40% 65.13% 219.21% -27.73% -88.36%
Free Cash Flow Firm Growth		 -148.54% -269.76% -225.63% -171.03% -0.39% -24.90% -16.99% -11.69% 40.80% 45.55% -17.10%
Invested Capital Growth		 -1.96% -1.09% 3.36% 6.90% -14.69% 47.67% 78.92% 113.84% -36.46% 22.29% 439.02%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 324.75% 66.18% 32.84% 55.05% 34.99% 11.77% -3.04%
EBITDA Q/Q Growth		 -13.94% -18.99% -30.04% -7.00% 28.60% 42.39% -17.86% 40.79% -141.23% 48.94% -63.58%
EBIT Q/Q Growth		 -13.98% -18.92% -29.75% -6.91% 28.44% 42.39% -18.38% 40.43% -141.87% 47.83% -59.06%
NOPAT Q/Q Growth		 -13.98% -18.92% -29.75% -6.91% 28.44% 42.39% -18.38% 40.48% -141.46% 47.70% -55.55%
Net Income Q/Q Growth		 -15.08% -13.63% -31.51% -3.00% 29.62% 44.45% -23.26% 42.27% -170.07% 48.70% -61.15%
EPS Q/Q Growth		 -13.86% -7.30% -28.80% 3.79% 30.70% 49.19% -32.80% 42.77% -167.37% 49.80% -27.45%
Operating Cash Flow Q/Q Growth		 -12.76% 5.87% -86.60% 9.53% 50.36% -55.99% 14.93% 47.07% 269.71% -267.14% -25.46%
Free Cash Flow Firm Q/Q Growth		 -51.17% -20.35% -35.68% -9.80% 44.00% -49.72% -27.10% -4.82% 70.32% -37.70% -173.34%
Invested Capital Q/Q Growth		 0.30% -18.81% 18.66% 3.37% -22.81% 45.79% 67.24% 163.47% -1,310.58% 69.13% 242.92%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 100.00% 93.97% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% -1,105.33% -185.81% -64.41% -57.15% -21.82% -39.00% -17.82% -30.05%
Operating Margin		 0.00% 0.00% 0.00% -1,110.38% -187.06% -64.84% -57.79% -22.18% -39.68% -18.57% -29.78%
EBIT Margin		 0.00% 0.00% 0.00% -1,110.38% -187.06% -64.84% -57.79% -22.20% -39.78% -18.57% -30.45%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -1,038.20% -172.04% -57.51% -53.36% -19.87% -39.75% -18.24% -30.32%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.21% 95.75% 97.04% 93.50% 91.97% 88.68% 92.34% 89.50% 99.93% 98.27% 99.55%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,016.96%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,012.07%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 974.60%
Return on Equity (ROE)		 -2,110.28% -123.98% -88.78% -106.27% -129.76% -80.35% -50.16% -36.30% -41.22% -42.49% -42.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,581.24% 0.00% 0.00% -462.72%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -23.18% -21.92% -13.88% -17.64% -10.82% -24.19% -15.46% -31.02%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -21.68% -20.16% -12.31% -16.29% -9.69% -24.17% -15.19% -30.88%
Return on Common Equity (ROCE)		 -2,110.28% -123.98% -88.78% -106.27% -129.76% -80.35% -50.16% -36.30% -41.22% -42.49% -42.35%
Return on Equity Simple (ROE_SIMPLE)		 -1,561.15% 0.00% -52.22% -59.55% -66.74% 0.00% -55.10% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -69 -82 -106 -114 -81 -47 -56 -33 -80 -42 -65
NOPAT Margin		 0.00% 0.00% 0.00% -777.26% -130.94% -45.39% -40.45% -15.53% -27.77% -13.00% -20.85%
Net Nonoperating Expense Percent (NNEP)		 -26.84% -7.29% -6.92% -6.67% -5.09% -1.88% -2.12% -1.13% -4.14% -2.30% -4.88%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.75% - - - -5.38% -6.70% -4.06% -8.26% -4.43% -7.34%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 6.03% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 724.72% 176.50% 133.99% 125.60% 96.77% 79.10% 82.35% 94.87%
R&D to Revenue		 0.00% 0.00% 0.00% 485.66% 110.56% 24.82% 32.18% 25.41% 60.57% 36.21% 34.91%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 1,210.38% 287.06% 158.81% 157.79% 122.18% 139.68% 118.57% 129.78%
Earnings before Interest and Taxes (EBIT)		 -99 -117 -152 -163 -116 -67 -79 -47 -114 -60 -95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -98 -116 -151 -162 -116 -67 -78 -46 -112 -57 -94
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 121.24 11.27 6.20 6.97 5.93 8.92 10.29 9.65 16.34 21.94 22.10
Price to Tangible Book Value (P/TBV)		 121.24 11.27 6.23 7.01 5.97 8.98 10.36 9.72 16.54 22.22 22.40
Price to Revenue (P/Rev)		 0.00 0.00 0.00 407.89 59.99 37.36 23.04 13.03 13.80 13.80 10.60
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 489.53 0.00 0.00 175.09
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 343.25 48.45 32.84 20.74 11.71 12.76 13.12 10.18
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 5.16 0.28 0.14 0.14 0.15 0.16 0.17 0.17 0.54 0.56 0.63
Long-Term Debt to Equity		 5.16 0.28 0.14 0.14 0.15 0.16 0.17 0.17 0.54 0.56 0.63
Financial Leverage		 -6.74 -1.37 -1.19 -1.19 -1.26 -1.15 -1.07 -1.05 -1.18 -1.08 -0.96
Leverage Ratio		 12.05 1.66 1.41 1.46 1.64 1.45 1.33 1.36 1.74 1.70 1.77
Compound Leverage Factor		 12.07 1.59 1.37 1.36 1.51 1.29 1.23 1.22 1.74 1.67 1.77
Debt to Total Capital		 83.76% 22.17% 12.01% 11.98% 13.09% 13.48% 14.24% 14.54% 35.19% 36.06% 38.51%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 83.76% 22.17% 12.01% 11.98% 13.09% 13.48% 14.24% 14.54% 35.19% 36.06% 38.51%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 16.24% 77.83% 87.99% 88.02% 86.91% 86.52% 85.76% 85.46% 64.81% 63.94% 61.49%
Debt to EBITDA		 -0.33 -0.31 -0.26 -0.22 -0.21 -0.24 -0.28 -0.39 -1.12 -1.16 -1.10
Net Debt to EBITDA		 0.34 1.37 2.09 1.80 1.63 1.64 1.73 2.23 2.56 2.20 1.54
Long-Term Debt to EBITDA		 -0.33 -0.31 -0.26 -0.22 -0.21 -0.24 -0.28 -0.39 -1.12 -1.16 -1.10
Debt to NOPAT		 -0.47 -0.43 -0.37 -0.31 -0.31 -0.34 -0.40 -0.55 -1.58 -1.62 -1.55
Net Debt to NOPAT		 0.48 1.95 2.97 2.55 2.31 2.33 2.45 3.15 3.60 3.09 2.18
Long-Term Debt to NOPAT		 -0.47 -0.43 -0.37 -0.31 -0.31 -0.34 -0.40 -0.55 -1.58 -1.62 -1.55
Altman Z-Score		 -0.38 9.10 12.34 13.26 7.77 12.56 13.75 11.29 7.35 11.25 9.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.36 5.38 9.39 8.72 5.98 6.10 5.91 5.11 3.44 4.01 3.50
Quick Ratio		 2.33 5.35 9.26 8.51 5.79 5.79 5.41 4.46 3.12 3.60 2.96
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -67 -81 -110 -120 -67 -101 -128 -134 -40 -55 -150
Operating Cash Flow to CapEx		 -25,050.15% -7,715.54% -41,780.67% -103,011.45% -8,598.72% -53,582.56% 0.00% 0.00% 9,317.39% 0.00% -4,350.09%
Free Cash Flow to Firm to Interest Expense		 -19.16 -20.35 -28.57 -32.92 -18.32 -28.85 -38.90 -41.19 -3.90 -6.62 -19.21
Operating Cash Flow to Interest Expense		 -24.24 -20.13 -38.86 -36.91 -18.21 -29.87 -26.96 -14.42 7.81 -16.09 -21.41
Operating Cash Flow Less CapEx to Interest Expense		 -24.33 -20.39 -38.96 -36.95 -18.42 -29.93 -26.96 -14.42 7.72 -16.04 -21.91
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.02 0.12 0.21 0.31 0.49 0.61 0.83 1.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.97 10.30 10.18 9.10
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.22 0.18 0.16 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 13.62 52.49 96.25 174.24 311.51 285.91 519.60 227.96
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.17 0.20 0.27 0.14 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.49 35.42 35.86 40.09
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 1,642.44 2,066.24 2,284.75 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 2,097.59 1,861.72 1,375.24 2,661.72 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -2,097.59 -219.28 721.49 -341.55 35.86 40.09
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -95 -113 -92 -89 -109 -59 -19 12 -149 -46 66
Invested Capital Turnover		 0.00 0.00 0.00 -0.16 -0.75 -2.09 -5.69 -13.44 -5.73 -18.19 48.78
Increase / (Decrease) in Invested Capital		 -1.84 -1.22 3.21 6.60 -14 54 73 101 -40 13 85
Enterprise Value (EV)		 2,580 4,049 4,329 5,024 3,721 5,916 6,584 6,036 9,448 12,577 11,531
Market Capitalization		 2,698 4,568 5,272 5,971 4,608 6,730 7,314 6,720 10,223 13,226 12,008
Book Value per Share		 $1.20 $20.53 $42.53 $40.22 $35.79 $34.59 $32.18 $31.35 $28.07 $26.54 $23.69
Tangible Book Value per Share		 $1.20 $20.53 $42.28 $39.99 $35.57 $34.37 $31.97 $31.14 $27.74 $26.21 $23.37
Total Capital		 137 521 967 974 894 872 829 814 965 943 884
Total Debt		 115 115 116 117 117 118 118 118 340 340 340
Total Long-Term Debt		 115 115 116 117 117 118 118 118 340 340 340
Net Debt		 -118 -519 -943 -946 -887 -814 -730 -684 -775 -649 -478
Capital Expenditures (CapEx)		 0.34 1.04 0.36 0.13 0.78 0.20 0.00 0.00 0.86 -0.39 3.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -97 -115 -99 -96 -118 -68 -27 4.83 -159 -53 26
Debt-free Net Working Capital (DFNWC)		 136 519 960 967 886 864 821 807 955 935 844
Net Working Capital (NWC)		 136 519 960 967 886 864 821 807 955 935 844
Net Nonoperating Expense (NNE)		 30 30 41 38 26 13 18 9.24 34 17 29
Net Nonoperating Obligations (NNO)		 -118 -519 -943 -946 -887 -814 -730 -684 -775 -649 -478
Total Depreciation and Amortization (D&A)		 0.81 0.90 0.82 0.74 0.78 0.45 0.87 0.80 2.24 2.41 1.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -657.38% -153.37% -37.53% -8.61% 0.94% -21.53% -5.55% 2.31%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 6,603.13% 1,153.22% 479.45% 258.60% 156.50% 128.98% 97.61% 74.53%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 6,603.13% 1,153.22% 479.45% 258.60% 156.50% 128.98% 97.61% 74.53%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50) ($3.32) ($1.90) ($5.08) ($2.55) ($3.25)
Adjusted Weighted Average Basic Shares Outstanding		 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M 22.09M 22.21M 22.48M 22.43M 29.03M
Adjusted Diluted Earnings per Share		 ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50) ($3.32) ($1.90) ($5.08) ($2.55) ($3.25)
Adjusted Weighted Average Diluted Shares Outstanding		 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M 22.09M 22.21M 22.48M 22.43M 29.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 19.74M 19.90M 21.31M 21.71M 21.81M 22.08M 22.20M 22.29M 22.71M 22.94M 23.06M
Normalized Net Operating Profit after Tax (NOPAT)		 -69 -82 -106 -114 -81 -47 -56 -33 -80 -42 -65
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -777.26% -130.94% -45.39% -40.45% -15.53% -27.77% -13.00% -20.85%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -1,038.20% -172.04% -57.51% -53.36% -19.87% -39.75% -18.24% -30.32%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -28.12 -29.51 -39.61 -44.46 -31.61 -19.15 -24.06 -14.47 -11.17 -7.18 -12.13
NOPAT to Interest Expense		 -19.68 -20.66 -27.73 -31.12 -22.13 -13.41 -16.84 -10.12 -7.80 -5.03 -8.30
EBIT Less CapEx to Interest Expense		 -28.22 -29.77 -39.71 -44.49 -31.82 -19.21 -24.06 -14.47 -11.25 -7.14 -12.62
NOPAT Less CapEx to Interest Expense		 -19.78 -20.92 -27.82 -31.16 -22.34 -13.46 -16.84 -10.12 -7.88 -4.98 -8.79
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Market context for Madrigal Pharmaceuticals (MDGL) based on the latest four years of quarterly statements shows a clear top-line ramp in 2025, a strong liquidity position, but ongoing profitability challenges and cash-burn from operating activities. The company ended Q4 2025 with solid revenue growth and an impressive gross margin for that quarter, while maintaining a substantial liquidity cushion through cash and short-term investments. However, net losses persist across most quarters, and operating cash flow remains uneven, with a notable cash burn in Q4 2025. Below are the key takeaways, organized by potential impact on investors.

  • Q4 2025 revenue and gross margin: Operating revenue of 321.083 million and total gross profit of 321.083 million with total cost of revenue at 0 (gross margin effectively 100%) suggest strong top-line momentum and favorable margin structure for the quarter.
  • 2025 revenue ramp: Revenue progressed from 137.25 million in Q1 2025 to 321.08 million in Q4 2025, indicating substantial year-over-year growth through the year.
  • Strong liquidity position: In Q3 2025, cash & equivalents were 295.7 million and short-term investments 814.1 million, with total current assets about 1.347 billion, providing a substantial liquidity runway.
  • Operating cash flow improvement in Q3 2025: Net cash from continuing operating activities was about 79.85 million in Q3 2025, signaling a period of positive cash generation despite subsequent volatility.
  • Asset growth and investment strength: Total assets reached roughly 1.362 billion by Q3 2025, driven by higher liquidity and investment balances, supporting the balance sheet resilience.
  • Investing and financing activity in late 2025: Net cash from continuing investing activities in Q4 2025 was about 27.58 million, and net cash from financing activities contributed around 8.96 million, indicating modest but ongoing liquidity management activity.
  • Funding mix remains modestly supportive: Ongoing equity issuance and financing activities across periods provided incremental liquidity, helping to fund the pipeline while the business burns cash.
  • Persistent losses: Quarterly net income figures remain negative in 2025 (Q3 -114.19 million; Q4 -58.58 million; Q1 -73.24 million; Q2 -42.28 million), pointing to ongoing profitability challenges.
  • Cash burn in core operations in Q4 2025: Net cash from operating activities in Q4 2025 was -133.46 million, highlighting a cash burn despite top-line strength.
  • High operating expense burn: SG&A and R&D are substantial (Q4 2025 SG&A 264.42 million and R&D 116.27 million; total operating expenses 380.69 million), contributing to the ongoing negative bottom line.
05/18/26 11:28 PM ETAI Generated. May Contain Errors.

Madrigal Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Madrigal Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Madrigal Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$288.28 million in 2025, rising from -$68.67 million in 2015. The previous period was -$465.89 million in 2024. See Madrigal Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Madrigal Pharmaceuticals' total operating income in 2025 was -$300.10 million, based on the following breakdown:
  • Total Gross Profit: $958.40 million
  • Total Operating Expenses: $1.26 billion

Over the last 10 years, Madrigal Pharmaceuticals' total revenue changed from $0.00 in 2015 to $958.40 million in 2025, a change of 95,840,300,000.0%.

Madrigal Pharmaceuticals' total liabilities were at $656.90 million at the end of 2025, a 128.2% increase from 2024, and a 1,233.1% increase since 2015.

In the past 10 years, Madrigal Pharmaceuticals' cash and equivalents has ranged from $306.25 thousand in 2015 to $331.55 million in 2022, and is currently $198.69 million as of their latest financial filing in 2025.

Over the last 10 years, Madrigal Pharmaceuticals' book value per share changed from -0.36 in 2015 to 26.54 in 2025, a change of -7,575.2%.


Related Companies

Financial statements for NASDAQ:MDGL last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
They're not telling you how bad this could get
Valuations are stretched to levels seen only a handful of times in the last hundred years — yet most retiremen...
Parkview Capital Group | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel